Cathay Biotech Inc. (688065) announced on November 25 that its revenue for the first three quarters of 2025 reached RMB2.545 billion, marking a year-on-year increase of 14.90%. Net profit rose by 30.56% YoY to RMB451 million.
The company is actively advancing the application development of its bio-based polyamide series and composite materials. In collaboration with China Merchants Group and downstream partners across various industries, Cathay Biotech is driving the establishment of an ecosystem for bio-manufacturing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments